BOSTON, MA--(Marketwired - January 28, 2016) - Pieris Pharmaceuticals, Inc. (PIRS), a biotechnology company advancing its proprietary Anticalin® bio therapeutic technologies, announced today that its President and CEO, Stephen Yoder, will present at the 18th Annual BIO CEO and Investor Conference. The conference is being held February 8 - 9, 2016, at the Waldorf Astoria Hotel in New York City.
Mr. Yoder is scheduled to present on Monday, February 8th at 9:30 am ET. The presentation will be webcast live and available for replay at: http://www.veracast.com/webcasts/bio/ceoinvestor2016/72107109727.cfm and on the investor relations section of the Company’s website at www.pieris.com.
Investors are also invited to request a one-on-one meeting with Pieris Pharmaceuticals management during the conference by submitting a request through BIO’s One-on-One Partnering™ system or by contacting a member of the Pieris’ investor relations team below.
About Pieris Pharmaceuticals:
Pieris Pharmaceuticals is a clinical stage biotechnology company that discovers and develops Anticalin-based drugs to target validated disease pathways in a unique and transformative way. Our pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Proprietary to Pieris, Anticalins are a novel class of protein therapeutics validated in the clinic and by partnerships with leading pharmaceutical companies. Anticalin®, Anticalins®are registered trademarks of Pieris. For more information visit www.pieris.com.
